Skip to content

The global system for funding drug development socializes the costs and privatizes the profits though a system of taxpayer-funded research, legal corporate tax havens, and intellectual property registrations to guarantee exclusive access to markets and to reduce corporate taxes, while selling identical formulations at wildly different prices.

Click image to download as a JPG.


Americans for Tax Fairness (2016). “Gilead Sciences Price Gouger, Tax Dodger,” July,

“What is the minimum cost per person to cure HCV?” Andrew Hill and Saye Khoo, Department of Pharmacology and Therapeutics, Liverpool University, UK; Bryony Simmons, MetaVirology Ltd, London, UK; Nathan Ford, University of Cape Town, South Africa. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, Malaysia, July 2013,

“Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries,” Andrew Hill, Saye Khoo, Joe Fortunak, Bryony Simmons, and Nathan Ford. Clin Infect Dis, first published online January 6, 2014

“Rapidly falling costs for new hepatitis C direct-acting antivirals (DAAs): Potential for universal access,” Dzintars Gotham, Melissa Barber, Joseph Fortunak, Anton Pozniak,

Back To Top